Overview

Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Investigation of pharmacodynamics (inhibition of oxidosqualene cyclase, MES as marker), effect on routine lipid profile parameters, safety and preliminary pharmacokinetics

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Pravastatin